ClinicalTrials.gg
TerminatedNCT05167448Updated Oct 26, 2026

A Study of ES104 in Patients With Metastatic Colorectal Cancer

A Phase 1/2 interventional study of ES104 and ES104 in Metastatic Colorectal Cancer, sponsored by Elpiscience (Suzhou) Biopharma, Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Elpiscience (Suzhou) Biopharma, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor's development strategy adjustment.
Updated Oct 26, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Enrollment
837th of 894
12 · median 80
Started
2022
with 96 others
Phase 1/2
95 of 1,139
44 open now
Registered
454th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 837th largest by enrollment of the 894 interventional ones that give a count, is one of 97 that started in 2022, is one of 95 in phase 1/2, and was the 454th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal cancer who have failed systemic therapies.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • ES104
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and the willingness to sign a written form.
  • Locally advanced or colorectal adenocarcinoma confirmed by pathology and not surgically resectable, having received systemic therapy and failed.
  • At least one is required ( v1.1)
  • performance status (ECOG PS) of 0 or 1.
  • Estimated , in the judgment of the investigator, of at least 12 weeks.
  • Adequate organ function, as assessed by the results of the laboratory tests specified in the protocol.
  • Male and female subjects of must be willing to use effective methods, from the time of signing informed consent and for the duration of study participation through 180 days following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Receipt of any systemic antitumor therapy within 28 days prior to the first dose of study drug.
  • Known history of severe allergy to any monoclonal antibody or study drug .
  • The subject has received or is receiving treatment in another clinical trial within 28 days prior to the first dose of study drug (except for participation in the overall survival follow-up of a study)
  • Receipt of antiplatelet agents or anticoagulants for therapeutic purposes within 14 days prior to the first dose of study drug.
  • Receipt of within 28 days prior to the first dose of study drug.
  • Prior history of allogeneic organ transplantation or allogeneic peripheral blood stem cell (PBSC)/bone marrow transplantation treatment.
  • Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per v5.0 before the first dose of study drug. Certain exceptions as defined in protocol apply.
  • Subjects with active brain or meningeal metastases.
  • Patients with other primary within 5 years before the first dose of study drug. Some exceptions as defined per protocol apply.
  • Major surgery or major traumatic injury within 28 days prior to the first dose of study drug (in the judgment of the Investigator).
  • History of cardiovascular disease as defined by the protocol within the past 5 years.
  • History of bleeding-related illness as defined by the protocol.
  • Presence of severe, unhealed or open wounds and active ulcers or untreated fractures.
  • Known history of (HIV) virus infection and/or acquired immunodeficiency syndrome.
  • Chronic active or active .
  • Active infection requiring systemic therapy 14 days prior to first dose of study drug.
  • Pregnant or nursing females.
  • Known history of alcohol or drug abuse.
  • Subjects with comorbidities or other conditions that may affect compliance with the protocol or are not suitable for participation in this study in the judgment of the Investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Cohort 1 Phase 1

    Drug: ES104

  • Experimental
    Cohort 2 Phase 1

    Drug: ES104

  • Experimental
    RP2D Phase 2

    Drug: ES104

Interventions

  • DrugTovecimigStudies of TovecimigTovecimig pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

  • DrugTovecimigStudies of TovecimigTovecimig pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

  • DrugTovecimigStudies of TovecimigTovecimig pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

06

What researchers measure

Primary outcomes

  1. Phase 1: The frequency and severity of adverse events of ES104

    The safety profile of ES104 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: 1-3 years

  2. Phase 2: The anti-tumor activity of ES104

    The Objective Remission Rate (ORR) will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.

    Time frame: 2-5 years

Secondary outcomes

  1. Phase 1: Maximum observed serum concentration (Cmax) of ES104

    Maximum observed serum concentration (Cmax) of ES104 will be measured.

    Time frame: 1-3 years

  2. Phase 1:Time to Cmax (Tmax) of ES104

    Time to Cmax (Tmax) of ES104 will be measured.

    Time frame: 1-3 years

  3. Phase 1:Area under the serum concentration time curve (AUC) of ES104

    Area under the serum concentration time curve (AUC) of ES104 will be measured.

    Time frame: 1-3 years

  4. Phase 1:The clearance of ES104

    A pharmacokinetic measurement of the volume of plasma from which ES104 is completely removed per unit time.

    Time frame: 1-3 years

  5. Phase 1: The immunogenicity of ES104

    The presence and the frequency of anti-drug antibodies (ADA) against ES104 will be measured.

    Time frame: 1-3 years

  6. Phase 1: The preliminary anti-tumor activity of ES104

    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.

    Time frame: 1-3 years

  7. Phase 2: The anti-tumor activity of ES104

    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.

    Time frame: 2-5 years

  8. Phase 2: The frequency and severity of adverse events of ES104

    The safety profile of ES104 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: 2-5 years

  9. Phase 2: The popPK profile of ES104

    The Cmin,ss、CL and Vd of ES104 will be measured.

    Time frame: 2-5 years

  10. Phase 2: The immunogenicity of ES104

    The presence and the frequency of anti-drug antibodies (ADA) against ES104 will be measured.

    Time frame: 2-5 years

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2022 to primary completion in Mar 2023, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion May 2026 → Mar 2023 and completion Jul 2026 → Mar 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2021
First posted
Dec 22, 2021
StartActual
Feb 25, 2022
Primary completionActual
Mar 24, 2023was May 2026
CompletionActual
Mar 24, 2023was Jul 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Sponsor's development strategy adjustment.
changed Oct 26, 2026
Primary completion
May 31, 2026→Mar 24, 2023 (actual)
Oct 26, 2026
Study completion
Jul 31, 2026→Mar 24, 2023 (actual)
Oct 26, 2026
Enrollment
58 (estimated)→12 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Terminated
    Why stopped Sponsor's development strategy adjustment.
    Primary completion May 31, 2026→Mar 24, 2023 (now actual)
    Study completion Jul 31, 2026→Mar 24, 2023 (now actual)
    Enrollment 58 (estimated)→12 (actual)
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05167448
Lead sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Responsible party
Sponsor
First posted
Dec 22, 2021
Start date
Feb 25, 2022
Primary completion
Mar 24, 2023
Completion
Mar 24, 2023
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovecimig

Start the discussion